New study seeks better ways to track rare lung disease

NCT ID NCT05297812

Ongoing Knowledge-focused Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 286 adults with Alpha-1 Antitrypsin Deficiency, a genetic condition that can damage the lungs and liver. Researchers use CT scans and blood tests over three years to see how lung density changes. The goal is to find biological markers that could help design better clinical trials for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could identify reliable biomarkers to speed up development of new treatments for Alpha-1 Antitrypsin Deficiency.
What could go wrong: This is an observational study, not testing a treatment. It may not find useful biomarkers, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency hereditary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPHA 1-ANTITRYPSIN DEFICIENCY GENETIC DISEASE

Contacts and locations

Locations

Boston University

Boston, Massachusetts, 02118, United States
Columbia University

New York, New York, 10032, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
National Jewish Health

Denver, Colorado, 80206, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States
University of California - Los Angeles

Los Angeles, California, 90095, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of North Carolina

Chapel Hill, North Carolina, 27514, United States
University of Utah

Salt Lake City, Utah, 84108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.